НПВС-нефропатии


В.В. Чельцов

ГУП “Медицинский центр Управления делами Мэра и Правительства Москвы”, Москва
Обсуждаются роль традиционных неселективных нестероидных противовоспалительных средств (НПВС) и селективных ингибиторов циклооксигеназы (ЦОГ)-2, а также основные механизмы развития НПВС-нефропатий. Рассматриваются разнообразные варианты поражения почек при назначении НПВС, наиболее значимые факторы риска, принципы лечения и возможные пути профилактики.

Литература


1. Singh G., Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J. Rheumatol. 1999;56(Suppl.):18–24.
2. Tamblin R., Berkson L., Dauphinee D. еt al. Unnecessary prescribing of NSAIDs and the management of NSAID-related gastropathy in medical practice. Ann. Intern. Med. 1997; 127: 429–438.
3. Steinmeyer J. Pharmacological basis for the therapy of pain and inflam-mation with nonsteroidal anti-inflammatory drugs. Arthritis Res. 2000; 2: 379–385.
4. Abramson S., Weaver A. Current state of therapy for pain and inflammation. Arthritis Res. Ther. 2005; 7(Suppl. 4):1–6.
5. Juni P., Rutjes A.W.S., Dieppe P.A. Are selective COX-2 inhibitors superior to traditional non-steroidal anti-inflammatory drugs? Adequate analysis of the CLASS trial indicates that this may not be the case. BMJ. 2002; 324: 1287–1288.
6. Sandler R.S., Halabi S., Baron J.A. et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. NEJM. 2003; 348: 883–890.
7. Zhang Y., Coogan P.F., Palmer J.R. et al. Use of nonsteroidal anti-inflammatory drugs and risk of breast cancer : the case-control surveillance study revisited. Am. J. Epidemiol. 2005;162:165–170.
8. Etminan M., Gill S., Samii A. Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer’s disease: systematic review and meta-analysis of observational studies. BMJ. 2003;327:128–131.
9. Moriland L. et. al. Management of rheumatoid arthritis: the historical context. J. Rheumatol. 2001; 286(6): 1431–1452.
10. Lewis S.C., Langman M.J., Laporte J.R. et al. Dose-response relationship between individual nonaspirinnonsteroidal anti-inflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: a meta-analysis based on individual patient date. Br. J. Clin. Pharmacol. 2002; 54: 320–326.
11. Pedersen A.K., Fitzgerald G.A. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase, NEJM. 1984,311:1206–1211.
12. Vane J.R. Inhibition of prostaglandin synthesis as the mechanism of action for aspirin-like drugs. Nature New Biol. 1971; 231: 232–235.
13. Masferrer J.L. et al. Selective regulation of cellular cyclooxygenase by dexametason and endotoxin in mice. J. Clin. Invest. 1990; 86: 1375–1379.
14. Davies N.M., Good R.L., Roupe K.A. et al. Cyclooxygenase-3: axiom, dogma, anomaly, enigma or splice error? – not as easy as 1,2,3. J. Pharm. Pharmaceut Sci. 2004; 7(2): 217–226.
15. Nasrallah R., Hebert R.L. Prostacyclin signaling in the kidney: implications for health and disease. Am. J. Physiol. Renal. Physiol. 2005; 289:235–246.
16. Satoh T., Ishikava Y., Kataoka Y. et al. CNS-specific prostacyclin ligands as neuronal survival-promoting factors in the brain. Eur. J. Neurosc. 1999; 11: 3115–3124.
17. Cheng Y., Austin S.C., Rocca B., et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science. 2002; 296: 539–541.
18. McLaughlin V.V., Genthner D.E., Panella M.М. et al. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. NЕJM. 1998; 338: 273–277.
19. Vachiery J.L., Naeije R. Treprostinil: stable long acting prostacyclin analog used for treatment pulmonary arteriolar hypertension. Expert. Rev. Cardiovasc. Ther. 2004; 2: 183–191.
20. Egan K.M., Lawson J.A., Fries S. et al. COX-2 derived prostacycline confers atheroprotection on female mice. Science. 2004; 306: 1954–1957.
21. Komhoff M., Grone H.J., Klein T. et al. Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: implication for renal function. Am. J. Physiol. 1997; 272: 460–468.
22. Qi Z., Cai H., Morrow J.D. et al. Differentiation of cyclooxygenase 1 and 2-derived prostanoids in mouse kidney and aorta, Hypertension. 2006; 48: 323–328.
23. Khan K.N.M., Paulson S.K., Verburg K.M. et al. Pharmacology of cyclooxygenase-2 inhibition in the kidney. Kidney Int. 2002; 61: 1210–1219.
24. Feeman R.H., Davis J.O., Villarreal D. Role of renal prostaglandins in the control of renin release. Circ. Res. 1984; 54: 1–9.
25. Farman N., Pradelles P., Bonvalet J.P. PGE2, 6-keto-PGF1α and TXB2 synthesis along the rabbit nephron. Am. J. Physiol. Renal. Рhysiol. 1987; 252: 53–59.
26. Schliebe N., Strotmann R., Busse K. et al. V2 vasopressin receptor deficiency causes changes in expression and function of renal and hypothalamic components involved in electrolyte and water homeostasis. Am. J. Physiol. Renal. Рhysiol. 2008; 295: 1177–1190.
27. Clive D.M., Stoff J.S. Renal syndromes associated with nonsteroidal antiinflammatory drugs. NEJM. 1984; 310:563–572.
28. Edwards R.M. Effects of prostaglandins on vasoconstrictor action in isolated renal arterioles. Am. J. Physiol. 1985; 248:779–789.
29. Bonventre J.V., Nemenoff R. Renal tubular arachidonic acid metabolism. Kidney Int. 1991; 39: 438–449.
30. Schlondorff D. Renal prostaglandin synthesis: sites of production and specific actions of prostaglandins. Am. J. Med. 1986; 81 (2B): 1–11.
31. Morrison A.R., Biochemistry and pharmacology of renal arachidonic acid metabolism. Am. J. Med. 1986; 80 (Suppl.1A): 3–11.
32. Pelavo J.C. Renal adrenergic effector mechanism: glomerular sites for prostaglandin interaction. Am. J. Physiol. 1988; 254 (23): 184–190.
33. Abdel-Kader Kh., Palevsky P. Acute kidney injury in the elderly. Clin. Geriatr. Med. 2009;25(3): 331–358.
34. Lydford S., McKechnie K., Dougall I. Pharmacological studies on prostanoid receptors in the rabbit isolated saphenous vein: a comparison with the rabbit isolated ear artery. Br. J. Pharmacol. 1996; 117: 13–20.
35. Reeves W.B., Foley R.J., Weinman E.J. Nephrotoxicity from nonsteroidal antiinflammatory drugs. South. Med. J. 1985; 78 (3):318–322.
36. Rodrigues F., Llinas M.T., Gonzales J.D. et al. Renal changes induced by a cyclooxygenase-2 inhibitor during normal and low sodium intake. Hypertension. 2000; 36: 276–281.
37. Rossat R.J., Maillard M., Nussberger J. et al. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin. Pharmacol. Ther. 1999; 66: 76–84.
38. Swan S.K., Rudy D.W., Lasserter K.C. et al. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial. Ann. Intern. Med. 2000; 133: 1–9.
39. Cheng H.F., Harris R.C. Cyclooxigenases, the kidney and hypertension. Hypertension. 2004; 43: 525–530.
40. Harris R.C. Cyclooxygenase-2 inhibition and renal physiology. Am. J. Cardiol. 2002; 89: 10–17.
41. Whelton A. Renal aspects of treatment with conventional nonsteroidal antiinflammatory drugs versus cyclooxygenase-2 specific inhibitors. Am. J. Med. 2001; 110: 33–42.


42. Zhang J., Ding E., Song Y. Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events. Meta-analysis of randomized trials. JAMA. 2006; 296 (1)3: 1619–1632.
43. Singh G. Recent consideration in nonsteroidal anti-inflammatory drugs gastropathy. Am. J. Med. 1998; 105: 31–38.
44. Sandhu G.K., Heyneman C.A. Nephrotoxic potential of selective cyclooxygenase-2 inhibitors. Ann. Pharmacother. 2004;38:700–704.
45. Ravnskov U. Glomerular, tubular and interstitial nephritis associated with nonsteroidal anti-inflammatory drugs. Evidence of a common mechanism. Br. J. Clin. Pharmacol. 1999; 47(2):203–210.
46. Schlondorff D. Renal complication of nonsteroidal anti-inflammatory drugs, Kidney International. 1993; 44: 643–653.
47. Singh A.K., Colvin R.B. Case 36-2003: a 68 year old women with impaired renal function. NEJM. 2003;349: 2055–2063.
48. Murray M.D., Brater D.C. Renal toxicity of the nonsteroidal anti-inflammatory drugs. Annu. Rev. Pharmacol. Toxicol. 1993; 33: 435–465.
49. Schlondorff D. Renal complications of non-steroidal anti-inflammatory drugs (NSAID). Nephrol. Dial. Transplant. 1996; 11(9):1907–1911.
50. Griffin M.R., Yared A., WayneA.R. Nonsteroidal anti-inflammatory drugs and acute renal failure in elderly persons. Am. J. Epidemiol. 2000;151:488–496.
51. Kohlhagen J., Katrib A., Stafford L. et al. Does regular use of non-steroidal anti-inflammatory drugs increase the risk of renal disease? Nephrology. 2002; 7(1):5–11.
52. Winkelmayer W.C., Waikar S.S., Mogun H. et al. Nonselective and cyclooxygenase-2 selective NSAID and acute kidney injury. Am. J. Med. 2008; 121(12): 1092–109.
53. Schneider V., Levesque L.E., Zhang B. et al. Association of selective and conventional nonsteroidal anti-inflammatory drugs with acute renal failure: a population-based, nested case-control analysis. Am. J. Epidemiol. 2006; 164(9):881–889.
54. Graham M.G. Acute renal failure to high-dose celecoxib. Ann. Intern. Med. 2001;135: 69–70.
55. Alper A.B., Meleg-Smith S., Krane N.K. Nephrotic syndrome and interstitial nephriris associated with celecoxib. Am. J. Kidney Dis. 2002; 40: 1086–1090. 56. Tabibian J.H., Tabibian N., Kaufman D.M. Late-onset celecoxibinduced combine hepato-nephrotoxicity. Br. J. Clin. Pharmacol. 2008; 66(1):150–151.
57. Abraham P.A., Keane W.F. Glomerular and interstitial disease induced by nonsteroidal anti-inflammatory drugs. Am. J. Nephrol. 1984; 4: 1–6.
58. Radford M.G., Holley K.E., Grande J.P. et al. Reversible membranous nephropathy associated with the use anti-inflammatory drugs. JAMA. 1996; 276: 466–469.
59. Porile J.L., Bakris G.L., Garella S.A. Acute interstitial nephritis with glomerulopathy due to nonsteroidal anti-inflammatory agents: a review of its clinical spectrum and effects of steroid therapy. J. Clin. Pharmacol. 1990; 30:468–475.
60. O’Callaghan C.A., Andrews P.A., Ogg C.G. Renal disease and use of topical nonsteroidal anti-inflammatory drugs. BMJ. 1994;308:110–111.
61. Fellner S.K. Piroxicam induced acute interstitial nephritis and minimal change nephritic syndrome. Am. J. Nephrol. 1985;5:142–143.
62. Kleinknecht D., Landais P., Goldfarb B. Analgesis and nonsteroidal antiinflammatory drug-associated acute renal failure: a prospective collaborative study. Clin. Nephrol. 1986; 25: 275–281.
63. Huerta C., Castellsague J., Varas-Lorenzo C. et al. Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population. Am. J. Kidney Dis. 2005; 45: 531–539.
64. Rossert J. Drug-induced acute interstitial nephritis. Kidney Int. 2001; 60: 804–817.
65. Sandler D.P., Burr R., Weinberg C.R. Nonsteroidal anti-inflammatory drugs and the risk for chronic renal disease. Ann. Intern. Med. 1991; 115: 165–172.
66. Buysen J.G.M., Houthoff H.J., Krediet R.T. et al. Acute Interstitial Nephritis: A Clinical and Morphological Study in 27 Patients. Nephrol. Dial. Transplant. 1990; 5: 94–99.
67. Schilliger F., Montagnac R., Milcent T. Membranous glomerolonephritis after diclofenac treatment. Kidney Int. 1987; 32: 428–429.
68. Kim M.J., Heim M., Mayer M. Effect of corticosteroids during ongoing drug exposure in pantoprazole-induced interstitial nephritis. Nephrol. Dial. Transpl. 2010; 25(5): 1716–1719.
69. Szalat A., Krasilnikov I., Bloch A. et al Acute renal failure and interstitial nephritis in a patient treated with rofecoxib: case report and review of the literature. Arthritis Rheum. 2004; 51(4):670–673.
70. Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundation and clinical implications. Am. J. Med. 1999;106: 13–24.
71. Gertz B.J., Krupa J.A., Sperling R.S. et al. A comparison of adverse renovascular experience among osteoarthritis patients with rofecoxib and comparator nonselective non-steroidal anti-inflammatory agents. Curr. Med. Res. Opin. 2002; 18: 82–91.
72. Osterhaus J.T., Burke T.A., May C. et al Physician-reported management of oedema and destabilized blood pressure in cyclooxygenase-2-specific inhibitor users with osteoarthritis and treated hypertension. Clin. Ther. 2002; 24: 969–989.
73. CollantesE., Curtis S.P., Wing Lee K. A multinational randomized controlled clinical trial of etoricoxib in the treatment of rheumatoid arthritix. BMC Family Prac. 2002;(3): 1–10.
74. Chang I., Harris R.C. Are all COX-2 inhibitors created equal? Hypertension. 2005;45:178–180.
75. Мухин Н.А. Избранные лекции по внутренним болезням. М.: “Литтерра” 2006. С. 111.
76. Gurwitz J.H., Everit D.E., Monane M. et al. The impact of ibuprofen on the efficacy of antihypertensive treatment with hydrochlorothiazide in elderly persons. J. Gerontol. 1996; 51: 74–79.
77. Polonia J., Boaventura I., Gama G. et al. Influence of non-steroidal antiinflammatory drugs on renal funciton and 24 h ambulatory blood pressure-reducing effect of enalapril and nifedipine gastrointestinal therapeutic system in hypertensive patients. J. Hypertens. 1995; 13: 925–931.
78. Sheridan R., Montgomery A.A., Fahey T. NSAID use and BP in treated hypertensives: a retrospective controlled observational study. J. Human. Hypertension. 2005; 19: 445–450.
79. Miyataka M., Rich K.A., Yamamoto T. et al. Nitric oxide, anti-inflammatory drugs on renal prostaglandins and cyclooxygenase-2. Hypertension. 2002; 39: 785–789.
80. Schnitzer Th.J., Hochberg M.C., Marrero Ch.E. et al. Efficacy and Safety of naproxcinod in patients with osteoarthritis of the knee: a 53- week prospective randomized multicenter study. Seminar in Arthritis and Rheumatism. 2011; 40(4):285–297.
81. Nasser S.M., Patel M., Bell G.S., et al. The effect of aspirin desensitiza-tion on urinary leukotriene E4 concentrations in aspirin-sensitive asthma. Am. J. Respir. Crit. Care Med. 1995; 151: 1326–1330.
82. Nickerson-Nutter C.L., Medvedeff E.D. The effects of leucotriene synthesis inhibition in models of acute and chronic inflammation. Arthritis Rheum. 1996; 39: 512–521.
83. Gambaro G., Perazella M.A. Adverse renal effects of anti-inflammatory agents: evaluation of selective and nonselective cyclooxygenase inhibitors. J. Intern. Med. 2003; 253(6): 643–652.
84. Whelton A. Nephrotoxicity of non-steroidal anti-inflammatory drugs: physiologic foundation and clinical implication. Am. J. Med. 1999; 106: 13–24.
85. Celotti F., Laufer S. Anti-inflammatory drugs: new multitarget compounds to face an old problem. The dual inhibition concept. Pharmacol. Res. 2001; 43: 429–436.
86. Algate D.R. et al General pharmacology of [2,2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2,3-dihydro-1H-pirrolizine-5-yl]-acetic acid in experimental animals. Arzneimittel-Forsching. 1995; 45: 159–165.


Об авторах / Для корреспонденции


Чельцов В.В. – профессор, главный специалист ГУП “Медицинский центр Управления делами Мэра и Правительства Москвы”, д.м.н.
E-mail: vcheltsov@mail.ru


Похожие статьи


Бионика Медиа